Predictive Value of the Zhang Scoring System for Imatinib Failure in Chronic Myeloid Leukemia: A Comparative Analysis with Established Prognostic Models.

Authors

Hakan Oral, Ümit Yavuz Malkan, Elifcan Aladağ Karakulak, Haluk Demiroğlu, Hakan Göker, İbrahim Celalettin Haznedaroğlu

Published in

Turkish journal of haematology : official journal of Turkish Society of Haematology. Oct 27, 2026. Epub Oct 27, 2026.

Abstract

The aim of this study was to evaluate the predictive performance of the Zhang score in comparison with other chronic myeloid leukemia (CML) risk scores for predicting imatinib treatment failure.
A total of 201 patients with CML treated between January 1, 2000, and January 10, 2025, were included [94 (46.7%) female and 107 (53.3%) male; mean age 47 ± 16 years; median follow-up 107.0 months (minimum-maximum) (6.4-359.6)].
Compared with the Sokal, Hasford, EUTOS, and ELTS scores, the Zhang score demonstrated the highest discriminative ability for predicting treatment failure, with the highest 5-year time-dependent AUC (0.775, 95% CI 0.700-0.849). In competing-risk regression analysis, both the intermediate-risk (subdistribution hazard ratio (SHR)=5.36, 95% CI 2.19-13.10; p<0.001) and high-risk (SHR=11.40, 95% CI 4.49-29.00; p<0.001) Zhang groups were significantly associated with treatment failure compared with the low-risk group.
In conclusion, the Zhang score showed better predictive performance than the other four CML scoring systems for first-line imatinib treatment failure.

PMID:
42935240
Bibliographic data and abstract were imported from PubMed on 27 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.